Frexalimab is a medication being studied for its potential to help people with certain kidney conditions, specifically primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD). These conditions can cause the kidneys to leak protein into the urine, which is not normal. Frexalimab is being tested to see if it can reduce this protein leakage, which might help improve kidney function and overall health.

SAR442970 is another medication included in the study, aimed at treating kidney conditions like FSGS and MCD. The goal of using SAR442970 is to see if it can lower the amount of protein that leaks into the urine. By doing so, it may help protect the kidneys and improve the health of people with these conditions.

Rilzabrutinib is also part of the clinical trial, and it is being tested for its effectiveness in treating FSGS and MCD. This medication is being evaluated to determine if it can help reduce proteinuria, which is the presence of excess protein in the urine. By reducing proteinuria, rilzabrutinib may help improve kidney function and benefit patients with these kidney diseases.

Focal Segmental Glomerulosclerosis (FSGS) – Focal Segmental Glomerulosclerosis is a disease that affects the kidney’s filtering units, known as glomeruli. It is characterized by scarring (sclerosis) in some of the glomeruli, which can lead to proteinuria, where protein is lost in the urine. Over time, this scarring can impair kidney function, leading to a decrease in the kidneys’ ability to filter waste from the blood. The disease can progress at varying rates, and the extent of kidney damage can differ among individuals. FSGS can occur as a primary condition or secondary to other diseases. The exact cause of primary FSGS is often unknown, but it involves immune system dysfunction.

Minimal Change Disease (MCD) – Minimal Change Disease is a kidney disorder that leads to nephrotic syndrome, characterized by high levels of protein in the urine, low levels of protein in the blood, swelling, and high cholesterol. Despite significant proteinuria, the kidney tissue appears nearly normal under a regular microscope, hence the name “minimal change.” The disease primarily affects children but can also occur in adults. The exact cause of MCD is not well understood, but it is believed to involve immune system abnormalities. The condition can lead to a rapid onset of symptoms, but kidney function typically remains normal. MCD is often responsive to treatment, although relapses can occur.